Xu, Q., He, S., & Yu, L. (2021). Clinical benefits and safety of FMS-like tyrosine kinase 3 inhibitors in various treatment stages of acute myeloid leukemia: A systematic review, meta-analysis, and network meta-analysis. Frontiers in oncology, 11, . https://doi.org/10.3389/fonc.2021.686013
Chicago-Zitierstil (17. Ausg.)Xu, Qingyu, Shujiao He, und Li Yu. "Clinical Benefits and Safety of FMS-like Tyrosine Kinase 3 Inhibitors in Various Treatment Stages of Acute Myeloid Leukemia: A Systematic Review, Meta-analysis, and Network Meta-analysis." Frontiers in Oncology 11 (2021). https://doi.org/10.3389/fonc.2021.686013.
MLA-Zitierstil (9. Ausg.)Xu, Qingyu, et al. "Clinical Benefits and Safety of FMS-like Tyrosine Kinase 3 Inhibitors in Various Treatment Stages of Acute Myeloid Leukemia: A Systematic Review, Meta-analysis, and Network Meta-analysis." Frontiers in Oncology, vol. 11, 2021, https://doi.org/10.3389/fonc.2021.686013.